New members

We welcome the following 21 companies as new members:

Actar AB, Aprea AB, Athera Biotechnologies AB, Avaris AB, Axelar AB, BioArctic Neuroscience AB, ClanoTech AB, Cogmed Systems AB, Dilafor AB, Isconova AB, IMED AB, Inhalation Sciences in Sweden AB, Karolinska Development AB, Lipopeptide AB, Mercodia AB, NeoDynamics AB, NovaSAID AB, Octapharma AB, SoftCure Pharmaceuticals AB, Syntagon AB and XSpray Micropartcles AB.

We welcome the following company as new partner:

Advokatfirman Delphi i Stockholm AB.

	1/3 > >>

1/3 > >>

Actar AB
Actar is a drug discovery company based on the Karolinska Institutet campus and is a part of the Karolinska Institutet´s innovation system. Actar explores innovative drug targets in multiple therapeutic areas resulting from academic research and collaborates with the academic researchers to perform ...

Advokatfirman Delphi i Stockholm AB
Delphi is one of the leading independent law firms in Sweden with offices in Stockholm, Gothenburg, Malmö, Linköping and Norrköping. We have expert knowledge in all areas of commercial law. As a full-service law firm we provide our clients with a complete and extensive offer of legal services based ...

Aprea AB
Aprea AB develops target specific drugs for the treatment of cancer with non- functional p53, associated with resistance to conventional cytostatics. Aprea's Investigational Product, APR-246, is in clinical Phase I. The inclusion has started in June 2009 with patients with refractory hematologic ...

Athera Biotechnologies AB
Athera Biotechnologies develops novel products for risk assessment and treatment of cardiovascular disease (CVD). The company was founded to exploit findings on the immunological components in atherosclerosis, the inflammatory process leading to cardiovascular disease based on antibodies against ...

Avaris AB
Avaris AB develops new cell therapies for chronic infections, cancer and inherited diseases until proof of concept in humans (Phase II). The company is based on four technology platforms within cell and gene therapy. Research is done in-house and in close collaboration with academy, while ...

Axelar AB
Axelar AB is a biotechnology company that focuses on research related to the insulin-like growth factor-1 (IGF-1) receptor inhibitors and their applications in important human diseases, especially cancer. Axelar's overall objective is to develop innovative small-molecule compounds that inhibit the ...

BioArctic Neuroscience AB
BioArctic Neuroscience AB performs research to develop new treatments for Alzheimer's disease and other neurodegenerative disorders. The company's research strategy is based on previous research done at the Karolinska Institute and Uppsala University and is aimed at developing an antibody against ...

ClanoTech AB
Clanotech aims to deliver novel anti-angiogenic compounds, VEGFRs & Integrin inhibitors for the treatment of solid cancers and age related macular degeneration (AMD). Clanotech was founded in 2006 based on research by Prof. Yihai Cao, Karolinska Institutet. The chemical starting points were then ...

Cogmed Sverige AB
Cogmed develops and markets software-based working memory training products for improved attention. Products are a unique combination of breakthrough research, original software design and effective support methodology. Cogmed is a privately held company founded in Stockholm, Sweden in 2001. The ...

Dilafor AB
Dilafor AB develops pharmaceuticals from heparin with low anticoagulant activity. The company was initially built on a clinical finding that women treated with dalteparin,a low molecular weight heparin, had significantly shorter labor with fewer complications than controls. This effect was found to ...

	1/3 > >>

1/3 > >>